Connect Biopharma is trading 5.1% down at $1.96; no credible company-specific announcement dated September 11, 2026 was identified.

  • The latest disclosed item is a September 15 investor presentation.
  • Recent coverage highlights upcoming Phase 2 data rather than a new catalyst.
  • The broader market is rising, so the decline does not appear to follow overall market direction; no volume data was provided.